

Rui Adão

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8235957/publications.pdf>

Version: 2024-02-01

36
papers

682
citations

623734

14
h-index

580821

25
g-index

37
all docs

37
docs citations

37
times ranked

1086
citing authors

#	ARTICLE	IF	CITATIONS
1	Nicotinamide for the treatment of heart failure with preserved ejection fraction. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	109
2	<i>Bmpr2</i> Mutant Rats Develop Pulmonary and Cardiac Characteristics of Pulmonary Arterial Hypertension. <i>Circulation</i> , 2019, 139, 932-948.	1.6	74
3	Cardiotoxicidade associada À terapêutica oncológica: mecanismos fisiopatológicos e estratégias de prevenção. <i>Revista Portuguesa De Cardiologia</i> , 2013, 32, 395-409.	0.5	62
4	Loss of KCNK3 is a hallmark of RV hypertrophy/dysfunction associated with pulmonary hypertension. <i>Cardiovascular Research</i> , 2018, 114, 880-893.	3.8	52
5	Update on pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2019, 46, 204-215.	1.9	39
6	Persistent Pulmonary Hypertension of the Newborn: Pathophysiological Mechanisms and Novel Therapeutic Approaches. <i>Frontiers in Pediatrics</i> , 2020, 8, 342.	1.9	35
7	Pulmonary arterial hypertension: Basic knowledge for clinicians. <i>Archives of Cardiovascular Diseases</i> , 2016, 109, 550-561.	1.6	34
8	Distinct right ventricle remodeling in response to pressure overload in the rat. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2016, 311, H85-H95.	3.2	33
9	Neuregulin-1 improves right ventricular function and attenuates experimental pulmonary arterial hypertension. <i>Cardiovascular Research</i> , 2016, 109, 44-54.	3.8	33
10	Inside the heart of COVID-19. <i>Cardiovascular Research</i> , 2020, 116, e59-e61.	3.8	33
11	Cardiotoxicity associated with cancer therapy: Pathophysiology and prevention. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2013, 32, 395-409.	0.2	30
12	Urocortin 2 in cardiovascular health and disease. <i>Drug Discovery Today</i> , 2015, 20, 906-914.	6.4	25
13	<i>Kcnk3</i> dysfunction exaggerates the development of pulmonary hypertension induced by left ventricular pressure overload. <i>Cardiovascular Research</i> , 2021, 117, 2474-2488.	3.8	20
14	Urocortin-2 improves right ventricular function and attenuates pulmonary arterial hypertension. <i>Cardiovascular Research</i> , 2018, 114, 1165-1177.	3.8	19
15	Lead availability in soils from Portugal's Centre Region with special reference to bioaccessibility. <i>Environmental Geochemistry and Health</i> , 2012, 34, 213-227.	3.4	13
16	Neuregulin-1 attenuates right ventricular diastolic stiffness in experimental pulmonary hypertension. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2019, 46, 255-265.	1.9	11
17	Role of Ion Channel Remodeling in Endothelial Dysfunction Induced by Pulmonary Arterial Hypertension. <i>Biomolecules</i> , 2022, 12, 484.	4.0	11
18	An Overview of Circulating Pulmonary Arterial Hypertension Biomarkers. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	2.4	8

#	ARTICLE	IF	CITATIONS
19	Cardiovascular Effects of Urocortin-2: Pathophysiological Mechanisms and Therapeutic Potential. <i>Cardiovascular Drugs and Therapy</i> , 2019, 33, 599-613.	2.6	7
20	Mobile cardiology during the COVID-19 outbreak. <i>Cardiovascular Research</i> , 2020, 116, e149-e151.	3.8	7
21	Efficacy of the thromboxane receptor antagonist NTP42 alone, or in combination with sildenafil, in the sugen/hypoxia-induced model of pulmonary arterial hypertension. <i>European Journal of Pharmacology</i> , 2020, 889, 173658.	3.5	7
22	Improvement in left intraventricular pressure gradients after aortic valve replacement in aortic stenosis patients. <i>Experimental Physiology</i> , 2017, 102, 411-421.	2.0	5
23	Heart Failure with Preserved Ejection Fraction: a Pharmacotherapeutic Update. <i>Cardiovascular Drugs and Therapy</i> , 2022, , 1.	2.6	5
24	Urocortin-2 in Acute Heart Failure: Role as a Marker of Volume Overload and Pulmonary Hypertension. <i>Current Problems in Cardiology</i> , 2022, 47, 100860.	2.4	3
25	Scientists on the Spot: Inflammation in atherosclerosis. <i>Cardiovascular Research</i> , 2021, 117, e7-e8.	3.8	2
26	Avalanching nanoparticles bring new light to cardiovascular imaging. <i>Cardiovascular Research</i> , 2021, 117, e60-e63.	3.8	1
27	Effects of urocortin-2 on cellular Ca ²⁺ homeostasis in right heart failure induced by pulmonary artery hypertension. , 2018, , .		1
28	Cardiotoxicity of Cancer Chemotherapy“Recent Developments. , 2016, , 36-83.		1
29	Urocortins as biomarkers in cardiovascular disease. <i>Clinical Science</i> , 2022, 136, 1-14.	4.3	1
30	Pulmonary Valve Replacement: A New Paradigm with Tissue Engineering. <i>Current Problems in Cardiology</i> , 2023, 48, 101212.	2.4	1
31	Highlights from the ERS International Congress 2018: Assembly 13 “ Pulmonary Vascular Diseases. <i>ERJ Open Research</i> , 2019, 5, 00202-2018.	2.6	0
32	Highlights of American Heart Association Scientific Sessions 2020: a virtual experience. <i>Cardiovascular Research</i> , 2021, 117, e10-e12.	3.8	0
33	Scientist on the Spot: Exploring the cause and cure for pulmonary arterial hypertension. <i>Cardiovascular Research</i> , 2021, 117, e82-e83.	3.8	0
34	Abstract 20669: Urocortin-2 Improves Right Ventricular Function in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2014, 130, .	1.6	0
35	Activation of the Beta-3 adrenoceptor in experimental pulmonary hypertension. , 2018, , .		0
36	Urocortin-2 improves right ventricular function and attenuates experimental pulmonary arterial hypertension. , 2018, , .		0